Phase II Clinical Trial of Uncaria Tomentosa (Cat´s Claw) in Patients With Advanced Solid Tumors (cat´sclaw)

ABC Foundation (FUABC)

Status and phase

Unknown

Phase 2

Conditions

Solid Tumors

Treatments

Drug: uncaria tomentosa (cat´s claw)

Study type

Interventional

Funder types

Other

Identifiers

NCT02045719

ABC2013

Details and patient eligibility

About

Cat's claw (Uncaria tomentosa) is a native amazonic plant that exhibits anti-inflammatory and antitumor properties. Patients and methods: This prospective phase II study will assess the effects of a 100-mg dose of a dry extract of U. tomentosa three times per day on individuals with advanced solid tumors, with no further therapeutic options and with at least 2 months life expectancy. In addition, several biochemical and inflammatory parameters will be analyzed.

Enrollment

51 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

individuals with advanced solid tumors, with no further therapeutic options and with at least 2 moths life expectancy
individuals 18 years of age and older
creatinine levels up to twice the upper limit of normal (ULN)
alanine (ALT) and aspartate (ASP) transaminase levels up to twice the ULN and direct bilirubin (DB) levels up to 1.5 times the ULN
in cases with pre-existing liver disease, the ALT, ASP and DB levels could be up to 2.5 times the ULN

Exclusion criteria

pregnant and breastfeeding women
individuals using chemotherapy or other tumor-targeting antineoplastic treatments, except for antalgic radiotherapy
severe kidney or liver failure
known hypersensitiveness to the components of the medication used
past history of emotional disorders that could interfere with the data collection.